New Coronavirus Study Finds Hope for Long-Term Immunity

Media reported that the new coronavirus would continue to exist — a news released by WHO earlier this week, echoing Dr. Fauci’s view that the “possibility of eradicating SARS-CoV-2 is very low”. In other words, new coronary pneumonia is expected to become an epidemic, a new infectious disease that people must learn how to respond to.

New Coronavirus Study Finds Hope for Long-Term Immunity

Although the global response to the outbreak of new coronary pneumonia has made great progress in the past few months, there is still no cure. Doctors have experimented with several treatments and have seen promising results in the study, and now researchers are working on a new drug designed to prevent complications from the new coronavirus.

All these efforts will help us treat diseasemore and more effectively than before, and hopefully reduce the risk of death. The ultimate goal of this campaign, of course, is to be vaccinated all over the world, a process that could take years if the vaccine is effective. Once most people are immunized through direct contact with the new coronavirus or vaccination, they can achieve the group immunity that you’ve been hearing all along.

So how good can this immunity be? New research suggests that people may be able to get long-term immunization.

It is understood that the virus has been in humans for about six months, but this is still not enough to measure the immunity caused by infection. If immunization lasts only a few years, then the vaccine can provide limited protection, which means that new vaccines will have to be developed in the future. On the other hand, long-lasting immunization means that a single inoculation can provide long-term protection.

In response, researchers have begun to study a particular type of cell that is immune for long periods of time. They are killer T-cells, which can target infected cells and destroy them.

Two teams have shown that if an infected person has the virus-specific T-cells, it can help them recover. In addition, some patients who are not infected with SARS-CoV-2 may already have T-cells protected from one of the four other human coronaviruses we already know.

Immunologists at the La Jolla Institute of Immunology published a study in the journal Cell. The study said the observed new coronary pneumonia survivors carried auxiliary T-cells (CD4), which identify the SARS-CoV-2 protein that binds the virus to human cells and penetrates it. Auxiliary T cells are known to activate B cells, which then produce antibodies. But they also have T-cells reacting to other SARS-CoV-2 proteins. 70% of patients with recovery also have virus-specific killer T cells (CD8).

The team also noted that half of the blood samples collected between 2015 and 2018 contained auxiliary T-cells that detected SARS-CoV-2 virus.

In addition, a similar picture was illustrated in a study published at the University Hospital of Charit in Germany in the form of a peer-reviewed study on medRxiv. Andreas Thiel and her team found that 15 of the 18 patients they observed identified T-cells that targeted the protoprotein. They then analyzed the blood of 68 uninfected people and found that 34 percent had T-cells that could identify SARS-CoV-2.

Researchers believe that past milder human coronaviruses may trigger a strong immune response after contracting the new coronavirus, which also works.

While these early findings are promising, more research is needed on the results. It is unclear how long the immunization will last and whether it is likely to re-infect in the future. “One of the reasons most people may be able to deal with this virus is that we may have some residual immunity when we are exposed to the common cold virus, ” says Steven Varga, an immunologist at the University of Iowa. “

“These papers are really helpful because they start to define the composition of T-cells for the immune response,” Columbia University virologist Angela Rasmussen told ScienceMag, adding that a strong immune response “bodes well for long-term protective immune development.” “